openPR Logo
Press release

Dravet Syndrome Treatment Market: Business Planning Research, Reviews & Comparison of Alternatives By 2026 With Top Competitors Epygenix Therapeutics, Ovid Therapeutics, GW Pharmaceuticals, Takeda Pharmaceutical Company, Zogenix

07-16-2019 03:18 PM CET | Health & Medicine

Press release from: Coherent Market Insights - Pharmaceutical Industry

Dravet Syndrome Treatment

Dravet Syndrome Treatment

Dravet syndrome (DS), also known as epilepsy with polymorphic seizures and polymorphic epilepsy in infancy (PMEI), is a severe and rare genetic dysfunction of the brain (epileptic encephalopathy). It usually begins in first year of life and remains throughout lifetime. Children suffering from dravet syndrome suffer from different type of seizures namely, myoclonic seizures, tonic-clonic seizures, absence seizures, atypical absence seizures, atonic seizures, focal aware or impaired awareness seizures (previously called partial seizures), and status epilepticus. Generally, combination of drugs are prescribed for the treatment of Dravet syndrome. Anticonvulsants such as stiripentol, topiramate, and Valproic acid are the most commonly used drugs for treatment of seizures and Dravet syndrome. In cases where intensity of seizures are not reduced by medication, certain devices are used to treat Dravet syndrome. Vagal nerve stimulation device is one such device, which delivers electrical impulses to the vagus nerve.

Get The PDF Brochure of This Business Report : https://www.coherentmarketinsights.com/insight/request-pdf/1548

Dravet Syndrome Treatment Market Drivers

Increasing research & development activities for the development of novel drugs for Dravet syndrome, and subsequently their approval in key regions such as North America and Europe is expected to fuel growth of the global Dravet syndrome treatment market in near future. In 2017, Epygenix Therapeutics, Inc.—a biopharmaceutical company—received U.S. Food and Drug Administration (FDA) orphan drug designation for its EPX-300, indicated for the treatment of Dravet syndrome. In 2017, Ovid Therapeutics—a U.S.-based biopharmaceutical company—received orphan drug designation for TAK-935/OV935 by U.S. Food and Drug Administration (FDA).

In February 2018, Zogenix Inc. announced FDA approval of breakthrough therapy designation to ZX-008, its Phase III drug for seizures associated with Dravet Syndrome. In 2017, OPKO Pharmaceuticals LLC, a subsidiary of OPKO Health, Inc., received orphan drug designation from U.S. FDA for its oligonucleotide-based AntagoNAT (CUR-1916) indicated for the treatment of Dravet Syndrome, and the company also received orphan drug designation for its CUR-1916 from European Commission during the same year. Furthermore, strategic collaborations among key players in market for the development and manufacturing of drugs indicated for treatment of Dravet syndrome is also expected to drive growth of the Dravet syndrome treatment market.

Dravet Syndrome Treatment Market Key Players

Key players operating in the Dravet syndrome treatment market include Epygenix Therapeutics, Inc., Ovid Therapeutics, GW Pharmaceuticals Plc., Takeda Pharmaceutical Company Ltd, Zogenix, Inc, OPKO Health Inc., Biocodex S.A., Biscayne Neurotherapeutics, Inc., and PTC Therapeutics, Inc. Key players in the market are focusing on receiving approval for their novel drugs, from major regulatory bodies such as FDA and European Commission. For instance, in 2017, Biscayne Neurotherapeutics, Inc., received an Orphan Drug designation from the U.S. FDA for its compound BIS-001 indicated for the treatment of Dravet syndrome.

Dravet Syndrome Treatment Market Regional Analysis

North America is expected to a hold dominant position in the global Dravet syndrome treatment market, owing to increasing initiatives and funding by various organizations to support the development of new treatment for Dravet syndrome. For instances, in 2017, The Dravet Syndrome Foundation—a U.S.-based non-profit organization dedicated to funding the highest caliber research on Dravet syndrome—funded a total amount of US$ 3,600,000 for the development of novel treatment methods for Dravet syndrome. In 2011, Dravet Syndrome Foundation granted an undisclosed amount to U.S.-based OPKO Health, Inc., to support the company's efforts to develop potential therapeutic agents for the treatment of Dravet syndrome.

Request For Customization : https://www.coherentmarketinsights.com/insight/request-customization/1548

The market in Europe is expected to exhibit significant growth in the Dravet syndrome treatment market, owing to increasing research and development activities being adopted by key players present in the region. For instance, GW Pharmaceuticals, a British biopharmaceutical company, developed Epidiolex (cannabidiol) based on an ingredient derived from marijuana. The company submitted new drug application (NDA) to the U.S. FDA for Epidiolex, in December 2017. If approved by the FDA, Epidiolex is expected to enter the market in the U.S. by mid of 2018.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Dravet Syndrome Treatment Market: Business Planning Research, Reviews & Comparison of Alternatives By 2026 With Top Competitors Epygenix Therapeutics, Ovid Therapeutics, GW Pharmaceuticals, Takeda Pharmaceutical Company, Zogenix here

News-ID: 1805226 • Views: 365

More Releases from Coherent Market Insights - Pharmaceutical Industry

Radiopharmaceuticals in Nuclear Medicine Market Advancements to Watch Out For 20 …
Coherent Market Insights released a new market study on 2018-2026 Radiopharmaceuticals Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. Ask For Sample Copy of Research
Outsourced Drug Discovery Market: Latest Advancements & Market Outlook 2019 to 2 …
Outsourced drug discovery is a contract-based process, which is conducted by the contract research organizations (CRO) and contract manufacturing organization (CMO). Contract research organization provides support to pharmaceutical, biotechnology, and medical device industries for drug discovery and development. CRO facilitates the various services such as biopharmaceutical development, biologic assay development, preclinical research, clinical trials, and pharmacovigilance, for drug discovery and development. Ask For a Sample Copy of This Business Report @
Cannabis Testing Services Market: New Business Opportunities and Investment Rese …
Cannabis market is highly influenced by rigorous legalization efforts, which are aiming for approval of cannabis for medicinal or recreational purpose. Various governments and regulatory authorities are taking efforts to legalize cannabis, owing to its medicinal benefits. Moreover, commercialization of cannabis-based products under the legalized standards require successful cannabis testing, which further results in lucrative growth opportunity for market players. Ask For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2976 Market
Global Myelodysplastic Syndrome (MDS) Treatment Market Balenced To Reach Insigni …
Myelodysplastic syndrome (MDS) is a disorder, which affects the bone marrow and produces immature blood cells. Bone marrow failure leads to lowering the levels of healthy blood cells circulation in the bloodstream. According to Seattle Cancer Care Alliance, around 80%-85% of people with MDS have more cells in their bone marrow than healthy people. According to National Organization for Rare Disorders, MDS deteriorates into a form of cancer in around

All 5 Releases


More Releases for Dravet

Dravet Syndrome Market 2022: Global Technology, Segmentation, Growth, Developmen …
Global Dravet Syndrome Market Size research report 2022 offers an in-depth assessment of revenue growth, market definition, segmentation, industry potential, influential trends for understanding the future outlook and current prospects for the market. The demand for refractive surgeries is anticipated to increase, attributed to the rise in the aging population and excessive use of digital devices, which has increased the screen time of the world population due to the COVID-19
Dravet Syndrome Treatment Market to Increase Exponentially During 2028
Coherent Market Insights report on the Dravet Syndrome Treatment Market studies past as well as current growth trends and opportunities to gain valuable insights of the indicators for the said market during the forecast period from 2021 to 2028. The report provides the overall market value of the Dravet Syndrome Treatment Market for the period of 2021 to 2028, with 2020 as the base year and 2028 as the forecast
Global Dravet Syndrome Market 2020 Industry Outlook, Comprehensive Insights, Gro …
Proactive role played by regulatory bodies in approving novel drugs will fuel the global Dravet syndrome market growth during the forecast period. Dravet syndrome is a severe form of epilepsy that occurs in the first year of life and becomes a lifelong condition characterized by frequent and prolonged seizure episodes. It is a rare disorder, affecting 1 in every 15,700 Americans, according to the National Institutes of Health. Since it's
Global Dravet Syndrome Thereapeutics Market 2020 - Biscayne Pharmaceuticals, Inc …
Global Dravet Syndrome Thereapeutics Market Survey Report: Supply, Demand, Production, Consumption, Competition, Vendors, Value Chain, Sales, Pricing, Statistical Analysis, Regional Analysis, Segments, Revenue, Volume, Historical Data, and Projections to 2025 Dravet Syndrome Thereapeutics The Dravet Syndrome Thereapeutics market research report consists of a detailed analysis of the Dravet Syndrome Thereapeutics market, in which major players are profiled. All the major companies engaged with the Dravet Syndrome Thereapeutics market are studied. The
Dravet Syndrome Treatment Market - Substantial Rise in Industrial Sectors to Off …
The newly released research at Up Market Research titled “2019 - 2025 Global Dravet Syndrome Treatment Market Report” provides data, information, brief analysis, company profiles, statistics for past years and forecasts for next few years. This report presents a comprehensive overview, market shares, and growth opportunities of Dravet Syndrome Treatment Market by product type, application, key manufacturers and key regions. Request Sample Copy Of this Report @ https://www.upmarketresearch.com/home/requested_sample/77681 Dravet Syndrome Treatment
Global Dravet Syndrome Treatment Market Status, Share, Significant Trends, Drive …
An up-to-date research report has been disclosed by Market Research Hub highlighting the title “Global Dravet Syndrome Treatment Market Insights, Forecast to 2025” which provides an outlook for current market value as well as the expected growth of Dravet Syndrome Treatment Market during 2018-2025. The report studies the casing heads market worldwide, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, size, growth, revenue, consumption, import